Latest Period
Q4 2025
Security Snapshot
Oncology Institute, Inc. - Common Stock, $0.0001 Par Value Per Share (TOI) Institutional Ownership
CUSIP: 68236X100
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
116
Shares (Excl. Options)
38,505,676
Price
$3.56
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 Par Value Per Share
- Symbol
- TOI on Nasdaq
- Shares outstanding
- 99,175,922
- Price per share
- $3.08
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 38,505,676
- Total reported value
- $137,199,596
- % of total 13F portfolios
- 0%
- Share change
- +3,814,679
- Value change
- +$13,731,282
- Number of holders
- 116
- Price from insider filings
- $3.08
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TOI - Oncology Institute, Inc. - Common Stock, $0.0001 Par Value Per Share is tracked under CUSIP 68236X100.
- 116 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 116 to 37 between Q4 2025 and Q1 2026.
- Reported value moved from $137,199,596 to $25,586,850.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 116 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 68236X100?
CUSIP 68236X100 identifies TOI - Oncology Institute, Inc. - Common Stock, $0.0001 Par Value Per Share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68236X100:
Significant Owners of Oncology Institute, Inc. - Common Stock, $0.0001 Par Value Per Share (TOI) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Chernett Jorey | 10% | $27,110,730 | 10,115,944 | Chernett Jorey | 13 Mar 2026 | |||
| SARIN RAVI YANG | 4.7% | $11,959,434 | 4,109,771 | Ravi Sarin | 26 Mar 2025 |
As of 31 Dec 2025, 116 institutional investors reported holding 38,505,676 shares of Oncology Institute, Inc. - Common Stock, $0.0001 Par Value Per Share (TOI). This represents 39% of the company’s total 99,175,922 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Oncology Institute, Inc. - Common Stock, $0.0001 Par Value Per Share (TOI) together control 34% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 4.8% | 4,748,635 | +4.5% | 0% | $16,905,141 |
| BlackRock, Inc. | 3.9% | 3,905,333 | +14% | 0% | $13,902,986 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.4% | 3,360,052 | 0% | 0.15% | $11,961,785 |
| CenterBook Partners LP | 3.1% | 3,029,312 | +12% | 0.53% | $10,784,351 |
| Kanen Wealth Management LLC | 3% | 2,976,144 | +62% | 3.3% | $10,712,000 |
| Balyasny Asset Management L.P. | 2.5% | 2,518,437 | +0% | 0.02% | $8,965,636 |
| JOSH ARNOLD INVESTMENT CONSULTANT, LLC | 2.5% | 2,459,809 | +1104% | 6.7% | $8,756,920 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,570,454 | +12% | 0% | $5,592,185 |
| WEXFORD CAPITAL LP | 1.5% | 1,533,456 | -2.4% | 1.4% | $5,459,100 |
| STATE STREET CORP | 1.4% | 1,351,624 | +20% | 0% | $4,811,781 |
| JANE STREET GROUP, LLC | 0.81% | 803,315 | +543% | 0% | $2,859,802 |
| RENAISSANCE TECHNOLOGIES LLC | 0.73% | 721,900 | -3.8% | 0% | $2,569,964 |
| BRC Group Holdings, Inc. | 0.67% | 663,376 | -18% | 1% | $2,361,619 |
| GOLDMAN SACHS GROUP INC | 0.58% | 570,424 | -16% | 0% | $2,030,709 |
| NORTHERN TRUST CORP | 0.5% | 499,244 | +7.4% | 0% | $1,777,308 |
| Massar Capital Management, LP | 0.4% | 400,000 | 0% | 0.28% | $1,424,000 |
| JPMORGAN CHASE & CO | 0.39% | 386,778 | +1483% | 0% | $1,376,930 |
| FourWorld Capital Management LLC | 0.39% | 382,700 | +6.9% | 1.3% | $1,362,412 |
| GatePass Capital, LLC | 0.36% | 360,000 | 0.66% | $1,281,600 | |
| FreeGulliver LLC | 0.36% | 355,672 | +69% | 0.57% | $1,266,192 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.3% | 295,150 | 0% | $1,050,734 | |
| UBS Group AG | 0.29% | 287,686 | -73% | 0% | $1,024,162 |
| LPL Financial LLC | 0.27% | 270,885 | +1.5% | 0% | $964,351 |
| TWO SIGMA INVESTMENTS, LP | 0.26% | 262,050 | -6.1% | 0% | $932,898 |
| Maven Securities LTD | 0.25% | 251,128 | +151% | 0.11% | $894,016 |
Institutional Holders of Oncology Institute, Inc. - Common Stock, $0.0001 Par Value Per Share (TOI) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 8,334,206 | $25,586,850 | -$5,716,849 | $3.07 | 37 |
| 2025 Q4 | 38,505,676 | $137,199,596 | +$13,731,282 | $3.56 | 116 |
| 2025 Q3 | 34,670,910 | $120,993,806 | +$10,399,257 | $3.49 | 107 |
| 2025 Q2 | 31,474,503 | $64,523,702 | +$31,211,552 | $2.05 | 78 |
| 2025 Q1 | 16,901,932 | $19,267,414 | +$2,727,938 | $1.14 | 42 |
| 2024 Q4 | 14,712,600 | $4,608,917 | -$2,191,797 | $0.31 | 30 |
| 2024 Q3 | 20,589,694 | $6,982,762 | +$385,704 | $0.33 | 34 |
| 2024 Q2 | 18,701,866 | $8,832,828 | -$155,334 | $0.46 | 38 |
| 2024 Q1 | 17,222,037 | $27,535,675 | -$2,492,260 | $1.58 | 44 |
| 2023 Q4 | 18,436,129 | $37,608,749 | +$6,554,810 | $2.04 | 44 |
| 2023 Q3 | 15,107,160 | $21,169,015 | +$1,157,191 | $1.40 | 36 |
| 2023 Q2 | 13,916,345 | $7,656,692 | -$4,490,020 | $0.55 | 37 |
| 2023 Q1 | 21,905,923 | $14,849,314 | -$1,309,674 | $0.68 | 37 |
| 2022 Q4 | 23,473,725 | $38,730,078 | -$1,269,944 | $1.65 | 37 |
| 2022 Q3 | 23,327,364 | $108,006,612 | +$6,672,135 | $4.63 | 39 |
| 2022 Q2 | 21,874,386 | $110,684,000 | +$2,844,383 | $5.06 | 33 |
| 2022 Q1 | 17,791,143 | $126,852,000 | -$752,294 | $7.13 | 27 |
| 2021 Q4 | 21,118,138 | $199,883,000 | +$185,679,000 | $9.75 | 21 |
| 2021 Q3 | 252,439 | $2,504,000 | +$2,504,000 | $9.92 | 1 |